RedHill Biopharma Gets Rights To Naloxegol, No Longer Core At AstraZeneca

Backed By Funds From HealthCare Royalty Partners

 
• By John Davis

Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.  

Stomach
GI diseases are a focus for RedHill Biopharma • Source: Shutterstock

More from Deals

More from Business